Skip to main content Skip to section navigation Skip to footer

XORTX Therapeutics Inc.

  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Advisory Board
  • Pipeline
    • Overview
    • XRx-026 for Gout
    • XRx-008 for Autosomal Dominant Polycystic Kidney Disease
    • XRx-101 for Coronavirus/COVID-19
    • 225 for Type 2 Diabetic Nephropathy
    • Publications
  • Technology
  • News & Media
    • Press Releases
    • Events
    • In the News
  • Investors
    • Overview
    • News & Events
    • Presentations
    • Company Info
    • Financial Info
    • Stock Data
    • SEC Filings
    • LIFE Offering
    • SEDAR+
    • Governance
  • Contact

Press Releases

News & Media

News & Media

  • Press Releases
  • Events
  • In the News
Oct 14, 2021 7:00am EDT

XORTX to Present at the LD Micro Main Event

Oct 13, 2021 7:55am EDT

XORTX Therapeutics Announces Pricing of US$12 Million Public Offering and Nasdaq Listing

Sep 20, 2021 4:46pm EDT

XORTX Therapeutics Announces Share Consolidation

Sep 02, 2021 2:26pm EDT

XORTX Therapeutics Reports Special Meeting Results

Sep 01, 2021 7:00am EDT

XORTX Announces Grant of European Patent

Aug 31, 2021 9:11am EDT

XORTX Announces New Clinical Advisory Board Member

Aug 13, 2021 5:00pm EDT

XORTX Therapeutics Calls Special Meeting of Shareholders

Jul 14, 2021 7:00am EDT

XORTX Therapeutics Strengthens Executive Team

Jun 30, 2021 7:00am EDT

Dr. Stephen Haworth Joins XORTX Management Team

Jun 17, 2021 7:00am EDT

XORTX Welcomes Jaqueline Le Saux to Board of Directors

  • arrow_back
  • 1…
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • …18
  • arrow_forward
rss_feed News RSS
©2025 XORTX Therapeutics Inc. All Rights Reserved.
Privacy Policy Disclaimer Sitemap